| Autor: |
Liu, Kaicai, zheng, Xiaomin, Dai, Jiaying, Hou, Changlong, Lu, Dong, Zhao, Bensheng, Yin, Shiwu, Wang, Guoxiang, Cao, Qisheng, Jiang, Bo, Gao, Songxue, Huang, Xudong, Xie, Jun, Zhang, Yudong, Li, Shuangsheng, Zhang, Aiwu, Yang, Wei, Wang, Song, Tan, Yulin, Shi, Wanyin |
| Zdroj: |
Academic Radiology; Oct2024, Vol. 31 Issue 10, p4034-4044, 11p |
| Abstrakt: |
Transarterial chemoembolization (TACE) plus molecular targeted therapies has emerged as the main approach for treating hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). A robust model for outcome prediction and risk stratification of recommended TACE plus molecular targeted therapies candidates is lacking. We aimed to develop an easy-to-use tool specifically for these patients. A retrospective analysis was conducted on 384 patients with HCC and PVTT who underwent TACE plus molecular targeted therapies at 16 different institutions. We developed and validated a new prognostic score which called ABPS score. Additionally, an external validation was performed on data from 200 patients enrolled in a prospective cohort study. The ABPS score (ranging from 0 to 3 scores), which involves only Albumin-bilirubin (ALBI, grade 1: 0 score; grade 2: 1 score), PVTT(I–II type: 0 score; III–IV type: 1 score), and systemic-immune inflammation index (SII,<550 × 1012: 0 score; ≥ 550 × 1012: 1 score). Patients were categorized into three risk groups based on their ABPS score: ABPS-A, B, and C (scored 0, 1–2, and 3, respectively). The concordance index (C-index) of the ABPS scoring system was calculated to be 0.802, significantly outperforming the HAP score (0.758), 6–12 (0.712), Up to 7 (0.683), and ALBI (0.595) scoring systems (all P < 0.05). These research findings were further validated in the external validation cohorts. The ABPS score demonstrated a strong association with survival outcomes and radiological response in patients undergoing TACE plus molecular targeted therapy for HCC with PVTT. The ABPS scoring system could serve as a valuable tool to guide treatment selection for these patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
